{"id":"https://openalex.org/W2038039477","doi":"https://doi.org/10.2174/0929867033457629","title":"Emerging Understanding of the Advantage of Small Molecules such as Hydroxypyridinones in the Treatment of Iron Overload","display_name":"Emerging Understanding of the Advantage of Small Molecules such as Hydroxypyridinones in the Treatment of Iron Overload","publication_year":2003,"publication_date":"2003-06-01","ids":{"openalex":"https://openalex.org/W2038039477","doi":"https://doi.org/10.2174/0929867033457629","mag":"2038039477","pmid":"https://pubmed.ncbi.nlm.nih.gov/12678676"},"language":"en","primary_location":{"id":"doi:10.2174/0929867033457629","doi":"https://doi.org/10.2174/0929867033457629","is_oa":false,"landing_page_url":"https://doi.org/10.2174/0929867033457629","pdf_url":null,"source":{"id":"https://openalex.org/S33159018","display_name":"Current Medicinal Chemistry","issn_l":"0929-8673","issn":["0929-8673","1875-533X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Medicinal Chemistry","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5020843793","display_name":"Robert C. Hider","orcid":"https://orcid.org/0000-0003-1330-5797","observed_orcids":["https://orcid.org/0000-0003-1330-5797"]},"institutions":[{"id":"https://openalex.org/I183935753","display_name":"King's College London","ror":"https://ror.org/0220mzb33","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I183935753"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Robert Hider","raw_affiliation_strings":["Department of Pharmacy, King's College London, UK. robert.hider@kcl.ac.uk","Department of Pharmacy, King\u2019s College, London, UK;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, King's College London, UK. robert.hider@kcl.ac.uk","institution_ids":["https://openalex.org/I183935753"]},{"raw_affiliation_string":"Department of Pharmacy, King\u2019s College, London, UK;","institution_ids":["https://openalex.org/I183935753"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5005000886","display_name":"Zu Dong Liu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zu Liu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.819,"has_fulltext":false,"cited_by_count":74,"citation_normalized_percentile":{"value":0.90412228,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"10","issue":"12","first_page":"1051","last_page":"1064"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10452","display_name":"Iron Metabolism and Disorders","score":0.9922000169754028,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10452","display_name":"Iron Metabolism and Disorders","score":0.9922000169754028,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10554","display_name":"Hemoglobinopathies and Related Disorders","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10790","display_name":"Heavy Metal Exposure and Toxicity","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2307","display_name":"Health, Toxicology and Mutagenesis"},"field":{"id":"https://openalex.org/fields/23","display_name":"Environmental Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/iron-overload","display_name":"iron overload","score":0.7820000052452087},{"id":"https://openalex.org/keywords/deferiprone","display_name":"deferiprone","score":0.8629999756813049},{"id":"https://openalex.org/keywords/hydroxypyridinone","display_name":"hydroxypyridinone","score":0.9419999718666077},{"id":"https://openalex.org/keywords/iron-chelation","display_name":"iron chelation","score":0.7889999747276306},{"id":"https://openalex.org/keywords/oral-iron-chelation","display_name":"oral iron chelation","score":0.6759999990463257},{"id":"https://openalex.org/keywords/iron-binding-affinity","display_name":"iron binding affinity","score":0.5640000104904175},{"id":"https://openalex.org/keywords/drug-metabolism","display_name":"drug metabolism","score":0.5600000023841858},{"id":"https://openalex.org/keywords/drug-distribution","display_name":"drug distribution","score":0.6930000185966492},{"id":"https://openalex.org/keywords/iron-overload-treatment","display_name":"iron overload treatment","score":0.32100000977516174}],"concepts":[{"id":"https://openalex.org/C2776517179","wikidata":"https://www.wikidata.org/wiki/Q749664","display_name":"Deferiprone","level":3,"score":0.9872127771377563},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5261202454566956},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.36929643154144287},{"id":"https://openalex.org/C21951064","wikidata":"https://www.wikidata.org/wiki/Q899212","display_name":"Combinatorial chemistry","level":1,"score":0.3549541234970093},{"id":"https://openalex.org/C2776672577","wikidata":"https://www.wikidata.org/wiki/Q419618","display_name":"Deferoxamine","level":2,"score":0.32888108491897583},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.31933900713920593},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2947348654270172}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007501","descriptor_name":"Iron","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D007502","descriptor_name":"Iron Chelating Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007502","descriptor_name":"Iron Chelating Agents","qualifier_ui":"Q000145","qualifier_name":"classification","is_major_topic":false},{"descriptor_ui":"D007502","descriptor_name":"Iron Chelating Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007502","descriptor_name":"Iron Chelating Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D008958","descriptor_name":"Models, Molecular","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D019190","descriptor_name":"Iron Overload","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.2174/0929867033457629","doi":"https://doi.org/10.2174/0929867033457629","is_oa":false,"landing_page_url":"https://doi.org/10.2174/0929867033457629","pdf_url":null,"source":{"id":"https://openalex.org/S33159018","display_name":"Current Medicinal Chemistry","issn_l":"0929-8673","issn":["0929-8673","1875-533X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Medicinal Chemistry","raw_type":"journal-article"},{"id":"pmid:12678676","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12678676","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current medicinal chemistry","raw_type":"Journal Article"},{"id":"pmh:oai:kclpure.kcl.ac.uk:publications/bd64526e-5463-42f7-b99a-958940530c1e","doi":null,"is_oa":false,"landing_page_url":"https://kclpure.kcl.ac.uk/portal/en/publications/bd64526e-5463-42f7-b99a-958940530c1e","pdf_url":null,"source":{"id":"https://openalex.org/S4306400216","display_name":"Research Portal (King's College London)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I183935753","host_organization_name":"King's College London","host_organization_lineage":["https://openalex.org/I183935753"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Hider, R C & Liu, Z D 2003, 'Emerging understanding of the advantage of small molecules such as hydroxypyridinones in the treatment of iron overload', Current Medicinal Chemistry, vol. 10, no. 12, pp. 1051 - 1064.","raw_type":"info:eu-repo/semantics/publishedVersion"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320334626","display_name":"Medical Research Council","ror":"https://ror.org/03x94j517"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2290990628","https://openalex.org/W3012973104","https://openalex.org/W1978527931","https://openalex.org/W2014153720","https://openalex.org/W2277820223","https://openalex.org/W2167689122","https://openalex.org/W4214531259","https://openalex.org/W2269916044","https://openalex.org/W2087490934","https://openalex.org/W1995255139"],"abstract_inverted_index":{"Deferiprone,":[0],"a":[1],"hydroxypyridin-4-one,":[2],"is":[3],"effective":[4],"at":[5],"facilitating":[6],"iron":[7,10,32],"removal":[8],"from":[9],"overloaded":[11],"patients,":[12],"when":[13],"administered":[14],"orally.":[15],"Some":[16],"problems":[17],"associated":[18],"with":[19,25],"deferiprone":[20],"are":[21,33],"discussed.":[22],"Hydroxypyridinone":[23],"analogues":[24],"improved":[26],"distribution,":[27],"metabolism":[28],"and":[29],"affinity":[30],"for":[31],"described.":[34],"In":[35],"particular":[36],"the":[37],"\"high":[38],"pFe(3+)\"":[39],"hydroxypyridin-4-ones":[40],"possess":[41],"considerable":[42],"clinical":[43],"potential.":[44]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}